Latest news with #Leqselvi
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Sun Pharma lines up $100 mn to commercialise niche products in FY26
Sun Pharmaceutical Industries has lined up a $100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 million. Elaborating on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies. "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added. Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi said. The drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25. "On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said. The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added.
Economic Times
5 days ago
- Business
- Economic Times
Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal
Sun Pharmaceutical Industries has lined up a USD 100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. ADVERTISEMENT The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. ADVERTISEMENT In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies. ADVERTISEMENT "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added. Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. ADVERTISEMENT "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. ADVERTISEMENT Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25. "On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said. The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added. (You can now subscribe to our Economic Times WhatsApp channel)
Time of India
5 days ago
- Business
- Time of India
Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal
Synopsis Sun Pharmaceutical Industries plans a USD 100 million investment to commercialize innovative products this fiscal year, focusing on its specialty business. The company will launch Unloxcyt and Leqselvi, while seeking a partner for MM-II development. Sun Pharma anticipates mid-to-high single-digit consolidated topline growth for FY26 and expects R&D spending to be 6-8% of sales.
Time of India
26-05-2025
- Business
- Time of India
JM Financial retains Buy on Sun Pharma, lowers target price to Rs 2,025
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel JM Financial has retained a Buy call on Sun Pharmaceutical Industries with a revised target price of Rs 2025 (earlier Rs 2,115). The current market price of Sun Pharmaceutical Industries is Rs 1683.25. The time period given by the analyst is a year when Sun Pharma price can reach the defined target. .Sun Pharmaceuticals Industries, incorporated in 1993, is a Large Cap company with a market cap of Rs 403952.04 Crore) operating in the Pharmaceuticals sector. Sun Pharmaceutical Industries' key products/revenue segments include Pharmaceuticals and Other Operating Revenue for the year ending the quarter ended 31-03-2025, the company has reported a Consolidated Total Income of Rs 13571.71 crore, down -4.03 % from last quarter Total Income of Rs 14141.08 crore and up 7.81% from last year same quarter Total Income of Rs 12,588.84 crore. The company has reported net profit after tax of Rs 2160.64 crore in latest company's top management includes S Shanghvi, D Shanghvi, V Valia, Goenka, Bijapurkar, Doshi, Asher, Hoffmann. Company has S R B C & Co. LLP as its auditors. As on 31-03-2025, the company has a total of 240 crore shares Pharma delivered a moderate Q4FY25, with results broadly in line with expectations. The company reported a top-line growth of 8% YoY in Q4FY25, with EBITDA and adjusted PAT growth of 22% and -11% YoY, respectively. Revenue, EBITDA, and adjusted PAT were down 1%, up 4%, and down 13% vs. JMFe. India formulations grew 13.6% YoY, maintaining its number-one rank with an 8.3% market share. Global specialty sales rose 8.6% YoY, driven by a 17% increase in Ilumya sales, while emerging markets (EM) grew 11.5% YoY in constant currency (CC), led by Romania, Russia, and Brazil. However, US formulations declined 2.5% YoY in CC due to weakness in the generic segment, despite growth in specialty brands like Ilumya and company launched 10 products each in India and the US in Q4FY25, strengthening its portfolio. Future growth is anchored in the Phase 3 data release of Ilumya in 2H CY25, the delayed launch of Leqselvi in 2QFY26, and the acquisition of Checkpoint Therapeutics, which enhances its oncology portfolio. With a focus on compliance for US plants, new product trials, and strategic M&A, the company is poised for >10% growth over FY25?28 on a large base. JM Financial maintains a positive outlook on the stock and reaffirms its BUY recommendation with a target price of Rs 2,025 (earlier Rs 2,115.)Promoters held 54.48 per cent stake in the company as of 31-Mar-2025, while FIIs owned 17.95 per cent, DIIs 18.48 per cent.
Business Standard
23-05-2025
- Business
- Business Standard
Sun Pharma drops after Q4 PAT slides 19% YoY to Rs 2,1450 cr
Sun Pharmaceutical Industries declined 3.08% to Rs 1,667 after the company's consolidated net profit declined 19% to Rs 2,149.88 crore, despite of 8.5% increase in revenue from operations to Rs 12,815.58 crore in Q4 FY25 over Q4 FY24. Profit before tax (PBT) jumped 15.6% YoY to Rs 3,254.35 crore in Q4 FY25. During the quarter, EBITDA stood at Rs 3,716.1 crore (including other operating revenues), up 22.4% with resulting EBITDA margin of 28.7%. India formulations sales were Rs 4,213 crore for Q4FY25, a growth of 13.6% over Q4 last year and accounted for 32.9% of total consolidated sales for the quarter. US formulation sales were $464 million for Q4FY25, lower by 2.5% over Q4 FY24 and accounted for 31.4% of total consolidated sales for the quarter. Formulation sales in emerging markets sales were $261 million for Q4FY25, a growth of 6.3% over Q4 last year and accounted for 17.6% of total consolidated sales for the quarter. Formulation sales in Rest of World (RoW) markets were $ 200 million for Q4FY25, a growth of 2.0% over Q4 FY24 and accounted for approximately 13.5% of total consolidated sales for the quarter. During the quarter, external sales of API were at Rs 533 crore, up 28.2%. The company said that its API portfolio supports its formulation business and API customers across geographies. During the quarter, R&D expense stood at Rs 816.6 crore, or 6.4% of sales. On full year basis, the companys consolidated net profit jumped 14.1% to Rs 10,929.04 crore on 9% increase in revenue from operations to Rs 52,041.25 crore in FY25 over FY24. The pharmaceutical company stated that it has a comprehensive product offering in the US market consisting of approved ANDAs for 542 products while filings for 117 ANDAs await US FDA approval, including 33 tentative approvals. Additionally, the portfolio includes 57 approved NDAs while 13 NDAs await US FDA approval. For the quarter, 9 ANDA were filed and 1 ANDA approval was received. Dilip Shanghvi, chairman and managing director of the company said, Our businesses delivered a robust performance for the year, driven by improving market share in India and growth in Global Specialty. The near-term pipeline in Global Specialty is promising, with products such as Leqselvi and Unloxcytthe latter through our recently announced checkpoint acquisitionoffering significant improvements in patient care. We look forward to specialty becoming an increasingly important part of our business. Meanwhile, the companys board recommended a final dividend of Rs 5.50 per share with a face value of Rs 1 each for FY25, subject to approval of shareholders approval at the ensuing annual general meeting (AGM). The company has fixed the record date as Monday, 7 July 2025. If the dividend approved by shareholders, it shall be paid on or before Friday, 8 August 2025. Sun Pharmaceutical Industries is the worlds leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets.
